Premium
IC‐P‐020: EVIDENCE OF AMYLOID ON FLORBETABEN‐PET IS ASSOCIATED WITH REDUCED EPISODIC MEMORY 10 YEARS PRIOR: RESULTS FROM THE WOMEN's HEALTHY AGEING PROJECT
Author(s) -
Yates Paul,
Villemagne Victor L.,
Robertson Joanne,
Dennerstein Lorraine,
Li Chuhui,
Desmond Patricia,
Masters Colin Louis,
Szoeke Cassandra,
Rowe Christopher Cleon
Publication year - 2014
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2014.05.024
Subject(s) - episodic memory , cognition , dementia , ageing , cognitive decline , standardized uptake value , positron emission tomography , psychology , medicine , recall , audiology , gerontology , neuroscience , disease , cognitive psychology
pants imaged with 11 C-PiB (PiB). e4 was present in 43% of the PiB cohort and 26% of the flute cohort while 54% of the PIB and 65% flute HC were classed as SMC by an affirmative answer to the question "Do you have difficulty with your memory?" and normal for age psychometric scores. PET images were acquired 90-110 mins post-injection of 18 F-flutemetamol and 40-70 minutes post-injection of 11 C-PiB. Neocortical SUVR were calculated using the pons as reference region for flutemetamol and a cutoff of 0.62 to define scans as low (Ab -) or high (Ab +) Ab burden. PiB was normalized to cerebellar cortex and a cut-off of 1.5 was used. Results: Compared to HC without memory complaint, SMC in both cohorts had significantly higher anxiety scores. Only in the flute cohort did the SMC have lower composite memory scores and have a higher prevalence of Ab + cases (OR 6.25, p1⁄40.002). However, in both cohorts a significantly increased prevalence of Ab + cases was present in, and confined to, the e4 carriers with SMC (66% vs 30% in e4 carriers without complaint in the PiB cohort; 63% vs 10% in the flute cohort). Conclusions: Subjective memory complaint is only associated with increased risk of preclinical AD in e4 carriers. Screening for SMC e4 carriers will provide amyloid positive scans in over 60% of subjects and may reduce the cost of amyloid imaging to identify individuals for preclinical AD trials.